New Twice-a-Year injection shows promise for lowering bad cholesterol
NCT ID NCT05888103
Summary
This study tested a new drug called inclisiran to see if it could safely lower 'bad' cholesterol (LDL-C) in Chinese adults. The 207 participants had elevated cholesterol but a low-to-moderate risk for heart disease and were not taking other cholesterol medications. For the first 6 months, some received the drug and others received a placebo, and then all participants received the drug for another 6 months to measure its long-term effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Fuzhou, Fujian, 350025, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
Zhongshan, Guangdong, 528403, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Changsha, Hunan, 410003, China
-
Novartis Investigative Site
Changsha, Hunan, 410011, China
-
Novartis Investigative Site
Hohhot, Inner Mongolia, 010017, China
-
Novartis Investigative Site
Changzhou, Jiangsu, 213004, China
-
Novartis Investigative Site
Xuzhou, Jiangsu, 221003, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330009, China
-
Novartis Investigative Site
Jinzhou, Liaoning, 121001, China
-
Novartis Investigative Site
Linyi, Shandong, 276000, China
-
Novartis Investigative Site
Taiyuan, Shanxi, 030002, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Tianjin, Tianjin Municipality, 300121, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Beijing, 100029, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Beijing, 101200, China
-
Novartis Investigative Site
Jinan, 250012, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200080, China
-
Novartis Investigative Site
Shanghai, 200120, China
-
Novartis Investigative Site
Tianjin, 300052, China
-
Novartis Investigative Site
Tianjin, 300140, China
Conditions
Explore the condition pages connected to this study.